Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial

Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial

2013 marks a milestone year for plasmid DNA vaccine development as a first-in-class cytomegalovirus (CMV) DNA vaccine enters pivotal phase 3 testing. This vaccine consists of two plasmids expressing CMV antigens glycoprotein B (gB) and phosphoprotein 65 (pp65) formulated with a CRL1005 poloxamer and...

Full description

Bibliographic Details
Main Authors: Michele Gerber, Alain P. Rolland, Jennifer A. Chaplin, Mary K. Wloch, Larry R. Smith
Format: Article
Language:English
Published: MDPI AG 2013-09-01
Series:Vaccines
Subjects:
plasmid DNA vaccine
cytomegalovirus (CMV)
glycoprotein B (gB)
phosphoprotein 65 (pp65)
poloxamer CRL1005
benzalkonium chloride (BAK)
hematopoietic cell transplant (HCT)
CMV end organ disease (EOD)
Online Access:http://www.mdpi.com/2076-393X/1/4/398

Internet

http://www.mdpi.com/2076-393X/1/4/398

Similar Items